AstraZeneca Pharma India's net profit for Q2 FY25 declined 27% to Rs 38 crore, while revenue rose to Rs 408 crore. The company's shares closed 3.74% lower on the BSE.
TSI India, a subsidiary of Findi, will acquire Tata Communications' subsidiary TCPSL for over Rs 330 crore, expanding its ...
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
AstraZeneca Pharma India reported a 27% decline in net profit for Q2 2024, amounting to Rs 38 crore. This is a drop from Rs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback